logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

In ampullary adenocarcinoma, adjuvant 5-FU is tied to better outcomes than gemcitabine

5-FU may be a potential first-line therapy in advanced disease, with gemcitabine secondary.